AIMMUNE THERAPEUTICS INC's ticker is AIMT and the CUSIP is 00900T107. A total of 158 filers reported holding AIMMUNE THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 0.54 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2020 | $560,000 | +100.0% | 16,247 | -3.0% | 0.00% | +200.0% |
Q2 2020 | $280,000 | +70.7% | 16,746 | +47.6% | 0.00% | 0.0% |
Q1 2020 | $164,000 | -75.2% | 11,342 | -42.7% | 0.00% | -66.7% |
Q4 2019 | $662,000 | +43.6% | 19,790 | -10.1% | 0.00% | 0.0% |
Q3 2019 | $461,000 | -3.2% | 22,024 | -3.7% | 0.00% | 0.0% |
Q2 2019 | $476,000 | -17.8% | 22,878 | -11.6% | 0.00% | 0.0% |
Q1 2019 | $579,000 | -5.5% | 25,886 | +1.1% | 0.00% | -25.0% |
Q4 2018 | $613,000 | -22.9% | 25,617 | -12.1% | 0.00% | -20.0% |
Q3 2018 | $795,000 | -1.9% | 29,144 | -3.2% | 0.01% | 0.0% |
Q2 2018 | $810,000 | -17.1% | 30,116 | -1.9% | 0.01% | -16.7% |
Q1 2018 | $977,000 | -20.8% | 30,709 | -5.9% | 0.01% | -33.3% |
Q4 2017 | $1,234,000 | +61.1% | 32,626 | +5.7% | 0.01% | +28.6% |
Q3 2017 | $766,000 | +28.7% | 30,881 | +6.7% | 0.01% | +16.7% |
Q2 2017 | $595,000 | +6.8% | 28,950 | +12.9% | 0.01% | 0.0% |
Q1 2017 | $557,000 | -15.5% | 25,647 | -20.4% | 0.01% | -14.3% |
Q4 2016 | $659,000 | – | 32,222 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital LLC | 1,240,000 | $25,966,000 | 57.34% |
Foresite Capital Management II, LLC | 2,605,499 | $54,559,000 | 11.53% |
Foresite Capital Management III, LLC | 611,893 | $12,813,000 | 4.89% |
Palo Alto Investors LP | 3,471,740 | $72,698,000 | 4.84% |
SANDERS MORRIS HARRIS LLC | 486,906 | $10,196,000 | 2.47% |
Eventide Asset Management | 3,084,000 | $64,579,000 | 2.13% |
Sofinnova Investments, Inc. | 346,770 | $7,261,000 | 0.66% |
EMERALD ADVISERS, LLC | 610,511 | $12,784,000 | 0.60% |
RICE HALL JAMES & ASSOCIATES, LLC | 752,358 | $15,754,000 | 0.56% |
EMERALD MUTUAL FUND ADVISERS TRUST | 587,464 | $12,301,000 | 0.54% |